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Abstract
Background: Type 2 diabetes may occur as a result of HIV infection and/or its treatment.
Gliclazide is a widely used drug for the treatment of type 2 diabetes. Efavirenz and nevirapine are
widely used non-nucleoside reverse transcriptase inhibitors for the treatment of HIV infection. The
role of Efavirenz and nevirapine on the pharmacodynamic activity of gliclazide is not currently
known. The objective of this study was to examine the effect of oral administration of efavirenz and
nevirapine on blood glucose and investigate their effect on the activity of gliclazide in rats (normal
and diabetic) and rabbits to evaluate the safety and effectiveness of the combination.
Methods: Studies in normal and alloxan induced diabetic rats were conducted with oral doses of
2 mg/kg bd. wt. of gliclazide, 54 mg/kg bd. wt. of efavirenz or 18 mg/kg bd. wt. of nevirapine and
their combination with adequate washout periods in between treatments. Studies in normal rabbits
were conducted with 5.6 mg/1.5 kg bd. wt. of gliclazide, 42 mg/1.5 kg bd. wt. of efavirenz or 14 mg/
1.5 kg bd. wt. of nevirapine and their combination given orally. Blood samples were collected at
regular time intervals in rats from retro orbital puncture and by marginal ear vein puncture in
rabbits. All the blood samples were analysed for blood glucose by GOD/POD method.
Results: Efavirenz and nevirapine alone have no significant effect on the blood glucose level in rats
and rabbits. Gliclazide produced hypoglycaemic/antidiabetic activity in normal and diabetic rats with
peak activity at 2 h and 8 h and hypoglycaemic activity in normal rabbits at 3 h. In combination,
efavirenz reduced the effect of gliclazide in rats and rabbits, and the reduction was more significant
with the single dose administration of efavirenz than multiple dose administration. In combination,
nevirapine has no effect on the activity of gliclazide in rats and rabbits.
Conclusion: Thus, it can be concluded that the combination of efavirenz and gliclazide may need
dose adjustment and care should be taken when the combination is prescribed for their clinical
benefit in diabetic patients. The combination of nevirapine and gliclazide was safe. However, further
studies are warranted.
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Background
The study of mechanisms of drug interactions is of much
value in selecting the drug concentrations to provide
rational therapy. The drug interaction studies assume
much importance especially for drugs that have narrow
margin of safety and where the drugs are used for pro-
longed period of time. Diabetes mellitus is one such met-
abolic disorder that needs treatment for prolonged
periods and maintenance of normal blood glucose level is
very important in this condition, since both hyperglyc-
emia as well as hypoglycemia is unwanted phenomenon
[1].
Diabetes mellitus is a chronic metabolic disorder charac-
terized by elevated blood glucose levels and disturbances
in carbohydrate, fat and protein metabolism and an
increased risk of complications from vascular disease [2].
Type-1 diabetes is due to decrease in the synthesis of insu-
lin and type-2 diabetes is characterized by hyperglycemia
in the context of insulin resistance and relative insulin
deficiency. There are estimated 143 million people world
wide sufferings from diabetes [3] and the number may
probably double by the year 2030 [4]. In India the preva-
lence rate of diabetes is estimated to be 1-5%.
Among the many metabolic perturbations that occur as a
result of Human Immuno Deficiency Virus (HIV) infec-
tion and its treatment, alterations in normal glucose
homeostasis remain a particularly prevalent and alarming
clinical change in affected patients [5]. Much of concern is
due to the recognition of the long-term complications of
insulin resistance and hyperglycemia and understood is
the context of the growing worldwide epidemic of type 2
diabetes mellitus [6].
Insulin resistance, impaired glucose tolerance and type 2
diabetes are conditions that are increasingly described in
HIV-1 infected subjects receiving highly active antiretrovi-
ral therapy (HAART). HAART generally includes nucleo-
side reverse transcriptase inhibitors and protease
inhibitors. Since many studies have suggested that PI ther-
apy [7] is linked to the development of metabolic compli-
cations, it is of importance to propose therapeutic
strategies with fewer side effects, such as the use of the
non-nucleoside reverse transcriptase inhibitors (NNRTIs)
and this approach appear successful to control HIV infec-
tion [8].
Efavirenz and nevirapine are NNRTIs used widely in com-
bination with other antiretroviral drugs to treat HIV-
infected patients. Recent reports demonstrated that a
switch from a protease inhibitor to nevirapine or efavirenz
results improvement of metabolic complications in HIV-
infected patients [9] and short-term improvement in insu-
lin resistance has been demonstrated with the substitu-
tion of nevirapine or efavirenz for the PI component of an
antiretroviral regimen [10-12]. However the effect of efa-
virenz and nevirapine in diabetic condition/oral hypogly-
cemic agents is unknown.
Oral hypoglycemic agents are used in the treatment of
type-2 diabetes, among which gliclazide, a second genera-
tion sulphonylurea derivative is preferred in therapy
because of its selective inhibitory activity towards pancre-
atic K+ ATP channels [13-15], antioxidant property [16-
18], low incidence of producing severe hypoglycemia
[19,20] and other haemobiological effects [21,22]. Gli-
clazide is known to act mainly by releasing insulin by
blocking K+ channels in the pancreatic β cells [23].
Since there is every possibility for the combined use of gli-
clazide and NNRTIs (efavirenz and nevirapine) in chronic
diabetics with associated HIV infection, the study is
planned to investigate the effect of efavirenz and nevirap-
ine on blood glucose and their effect on the activity of gli-
clazide in rats (normal and diabetic) and rabbits to
evaluate the safety and effectiveness of the combination
with respect to blood glucose level.
Methods
Gliclazide and NNRTIs (efavirenz and nevirapine) are the
gift samples from Micro Labs (Bangalore, India) and
Aurobindo Pharma Ltd (Hyderabad, India), respectively.
Alloxan monohydrate was purchased from LOBA Chemie
(Mumbai, India). Glucose kits (Span diagnostics) were
purchased from local pharmacy. All other reagents/chem-
icals used were of analytical grade.
Albino rats of either sex of 6 to 7 weeks of age, weighing
between 250-320 g and normal albino rabbits of either
sex of 3 months of age, weighing between 1.35-1.75 Kg
were used in the study. They were procured from National
Institute of Nutrition, Hyderabad, India. They were main-
tained under standard laboratory conditions at an ambi-
ent temperature of 25 ± 2°C and 50 ± 15% relative
humidity with a 12-h light/12-h dark cycle. Animals were
fed with a commercial pellet diet (Rayan's Biotechnolo-
gies Pvt Ltd., Hyderabad, India) and water ad libitum. They
were fasted for 18 h prior to the experiment and during
the experiment they were withdrawn from food and
water. The animal experiments were performed after prior
approval of the study protocol by the Institutional Animal
Ethics Committee and by the Government regulatory
body for animal research. (Reg. No. 516/01/A/CPCSEA).
The study was conducted in accordance with the guide-
lines provided by Committee for the Purpose of Control
and Supervision of Experiments on Animals (CPCSEA).Diabetology & Metabolic Syndrome 2009, 1:15 http://www.dmsjournal.com/content/1/1/15
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Study design
In clinical practice, NNRTIs and gliclazide in therapeutic
dose will be administered orally as antiretroviral and anti-
diabetic therapy, respectively. Hence, human oral thera-
peutic doses of the respective drugs were extrapolated to
rat/rabbit based on body surface area [24]. But the dose of
gliclazide for rat experiments was selected as 2 mg/kg bd.
wt based on the influence of dose-effect relationship of
gliclazide on blood glucose in normal rats. Efavirenz and
nevirapine were suspended in 0.5% CMC for oral admin-
istration [25,26]. Gliclazide solution was prepared by dis-
solving it in a few drops of 0.1 N NaOH then made up to
the volume with distilled water.
The study consists of two phases.
Phase-1: pharmacodynamic interaction study between
efavirenz and gliclazide
Phase-2: pharmacodynamic interaction study between
nevirapine and gliclazide
Each phase consists of 3 stages.
Stage-1: study in normal rats
Stage-2: study in diabetic rats
Stage-3: study in normal rabbits
Study in normal rats
A group of six rats was administered with 2 mg/kg bd. wt
of gliclazide, orally. The same group was administered
with interacting drug (efavirenz 54 mg/kg bd. wt. or nevi-
rapine 18 mg/kg bd. wt., orally) and the combination of
interacting drug and gliclazide. One week washout period
was maintained between treatments. After this single dose
interaction study the same group was continued with the
daily treatment of interacting drug (efavirenz/nevirapine)
for the next eight days with regular feeding. Later after 18
h fasting they were again given the combined treatment
on the ninth day.
Study in diabetic rats
Diabetes was induced in rats by the administration of
alloxan monohydrate in two doses, i.e. 100 mg and 50
mg/kg bd. wt intraperitoneally for two consecutive days
[27]. After 72 h, samples were collected from rats by
orbital puncture of all surviving rats and the serum was
analyzed for glucose levels. Rats with blood glucose levels
of 200 mg/dl and above were considered as diabetic and
selected for the study. The same treatment as described in
the study in normal rats was performed with a group of six
alloxan-induced diabetic rats.
Study in normal rabbits
A group of six rabbits was administered with 5.6 mg/1.5
kg bd. wt of gliclazide, orally. The same group was admin-
istered with interacting drug (efavirenz 42 mg/1.5 kg bd.
wt. or nevirapine 14 mg/1.5 kg bd. wt., orally) and the
combination of efavirenz and gliclazide. One week wash-
out period was maintained between treatments. After this
single dose interaction study the same group was contin-
ued with the daily treatment of interacting drug (efa-
virenz/nevirapine) for the next eight days with regular
feeding. Later after 18 h fasting they were again given the
combined treatment on the ninth day.
Collection of blood samples
Blood samples were withdrawn from retro orbital plexus
[28] of each rat at 0, 1, 2, 3, 4, 6, 8 and 12 h. Blood sam-
ples were withdrawn from the marginal ear vein of each
rabbit at 0, 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24 h. These blood
samples were analysed for blood glucose by GOD/POD
method [29] using commercial glucose kits.
Data and statistical analysis
Data were expressed as mean ± SEM. The significance was
determined by applying Student's paired 't' test.
Results
Pharmacodynamic interaction study between efavirenz 
and gliclazide
Gliclazide produced hypoglycemic activity with maxi-
mum biphasic reduction of 41.64 ± 0.80% and 38.70 ±
1.43% at 2 h and 8 h respectively in normal rats (Table 1).
Gliclazide produced antihyperglycemic activity with max-
imum biphasic reduction of 42.05 ± 1.73% and 44.05 ±
1.55% at 2 h and 8 h respectively in diabetic rats (Table 2).
Gliclazide produced hypoglycemic activity with maxi-
mum reduction of 34.25 ± 0.99% at 3 h in normal rabbits
(Table 3). Efavirenz alone has not produced any signifi-
cant effect on the blood glucose level of rats (normal and
diabetic) and rabbits (Tables 1, 2, 3). In combination efa-
virenz has reduced the gliclazide activity in rats and rab-
bits and the reduction was more significant with the single
dose treatment of efavirenz than multiple dose treatment
(Tables 1, 2, 3).
Pharmacodynamic interaction study between nevirapine 
and gliclazide
Gliclazide produced hypoglycemic activity with maxi-
mum biphasic reduction of 40.72 ± 0.56% and 37.46 ±
1.18% at 2 h and 8 h respectively in normal rats (Table 4).
Gliclazide produced antihyperglycemic activity with max-
imum biphasic reduction of 42.50 ± 1.40% and 44.46 ±
1.46% at 2 h and 8 h respectively in diabetic rats (Table 5).
Gliclazide produced hypoglycemic activity with maxi-
mum reduction of 36.18 ± 1.08% at 3 h in normal rabbits
(Table 6). Nevirapine alone has not produced any signifi-Diabetology & Metabolic Syndrome 2009, 1:15 http://www.dmsjournal.com/content/1/1/15
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cant effect on the blood glucose level of rats (normal and
diabetic) and rabbits (Tables 4, 5, 6). In combination nev-
irapine has no impact on the gliclazide activity in rats and
rabbits following single and multiple dose treatments
(Tables 4, 5, 6).
Discussion
HIV infected patients are likely to suffer with diabetes
mellitus [5] and hence most often antiretroviral drugs are
co-administered along with oral antidiabetic drugs. HIV
infection and diabetes are both chronic diseases that sig-
nificantly affect lifestyle. When they intersect, the treat-
ment regimens required for both diseases can be
overwhelming for patients. Frequently prescribed antiret-
roviral drugs belong to the class of non-nucleoside reverse
transcriptase inhibitors (NNRTIs) in HIV-infected
patients.
Efavirenz and nevirapine are commonly prescribed
NNRTIs for the treatment of HIV-infection and known to
be improving the metabolic complications in HIV-
infected patients [9-12]. However, there is no much evi-
dence on the activity of efavirenz/nevirapine alone in dia-
betic condition, as well as their effect on the activity of
gliclazide. Based on these factors the study was planned to
investigate the effect of efavirenz/nevirapine on blood
glucose and its effect on the activity of gliclazide in rats
(normal and diabetic) and rabbits to evaluate the safety
and effectiveness of the combination with respect to
blood glucose level. In our study, the multiple dose effect
of efavirenz and nevirapine on the gliclazide activity was
also studied for the influence of the long term treatment
with efavirenz/nevirapine since both are used for chronic
period.
Drug interactions are usually seen in clinical practice and
the mechanisms of interactions are evaluated usually in
animal models (rodents and non-rodents). We studied
the influence of efavirenz and nevirapine on the activity of
gliclazide in rats (normal and diabetic) and rabbits. The
normal rat model served to quickly identify the interac-
tion and diabetic rat model served to validate the same
response in the actually used condition of the drug. The
rabbit model is another dissimilar species to validate the
occurrence of the interaction. Since small amount of
blood was required for glucose analysis, the blood sam-
ples were collected by retro-orbital puncture as it was
reported to be good method when small samples of blood
were required [28]. Diabetes was induced with alloxan
Table 1: Mean percent blood glucose reduction in normal rats (N = 6)
Time
(h)
Gliclazide Efavirenz Efavirenz + Gliclazide 
(Single dose treatment)
Efavirenz + Gliclazide 
(Multiple dose treatment)
1 31.46 ± 1.39 -06.66 ± 2.95 24.40 ± 1.20*** 26.57 ± 1.09*
2 41.64 ± 0.80 -04.44 ± 1.44 33.77 ± 0.87** 36.26 ± 1.53*
3 28.21 ± 0.95 -02.94 ± 0.96 21.19 ± 1.15*** 22.26 ± 0.99**
4 24.21 ± 1.13 -00.06 ± 1.80 16.16 ± 0.79*** 18.68 ± 0.96***
6 31.47 ± 1.46 02.14 ± 1.49 23.34 ± 1.09*** 28.71 ± 1.85
8 38.70 ± 1.43 04.29 ± 1.09 28.36 ± 1.70*** 31.21 ± 2.03**
10 26.08 ± 1.02 06.86 ± 1.78 19.00 ± 1.44*** 20.45 ± 1.11**
12 12.27 ± 1.55 06.13 ± 1.59 08.27 ± 0.64 08.98 ± 1.02
***Significant at P < 0.001 compared to gliclazide control
**Significant at P < 0.01 compared to gliclazide control
*Significant at P < 0.05 compared to gliclazide control
Table 2: Mean percent blood glucose reduction in diabetic rats (N = 6)
Time
(h)
Gliclazide Efavirenz Efavirenz + Gliclazide 
(Single dose treatment)
Efavirenz + Gliclazide 
(Multiple dose treatment)
1 32.92 ± 1.95 -04.55 ± 2.55 24.83 ± 1.98** 28.26 ± 1.62
2 42.05 ± 1.73 -05.08 ± 2.46 30.02 ± 1.59*** 36.39 ± 1.89*
3 31.21 ± 1.74 -03.21 ± 2.41 20.70 ± 1.31*** 25.45 ± 1.93*
4 25.13 ± 1.77 -02.40 ± 2.24 16.78 ± 2.21*** 20.78 ± 1.36*
6 36.14 ± 1.56 03.99 ± 1.97 22.15 ± 1.34*** 30.12 ± 1.47*
8 44.05 ± 1.55 04.45 ± 2.26 32.01 ± 1.39*** 38.27 ± 1.42*
10 28.56 ± 1.87 05.39 ± 1.72 16.25 ± 2.25*** 20.89 ± 1.49**
12 24.66 ± 2.32 04.28 ± 1.53 08.49 ± 2.32*** 11.31 ± 2.17***
***Significant at P < 0.001 compared to gliclazide control
**Significant at P < 0.01 compared to gliclazide control
*Significant at P < 0.05 compared to gliclazide controlDiabetology & Metabolic Syndrome 2009, 1:15 http://www.dmsjournal.com/content/1/1/15
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monohydrate, since it was more economical and easily
available.
Gliclazide produced biphasic response in rat model when
administered alone, which may be due its biliary excre-
tion and entero hepatic cycling [30]. Such effect is not
seen in rabbit model. Gliclazide is known to produce
hypoglycemic/antihyperglycemic activity by pancreatic
[31-33] (stimulating insulin secretion by blocking K+
channels in the pancreatic β cells) and extra pancreatic
[34-36] (increasing tissue uptake of glucose) mechanisms.
Our study revealed the safety profile of efavirenz and nev-
irapine in diabetic condition also, with respect to blood
glucose levels. However, contrary to the theoretical expec-
tation, the activity of gliclazide was reduced in the pres-
ence of efavirenz in rats (normal and diabetic) and rabbits
and it confirms the presence of potential interaction
between efavirenz and gliclazide. The impact of efavirenz
on the activity of gliclazide was more significant following
single dose administration.
In vitro studies have shown that efavirenz inhibits
CYP2C9, CYP2C19 and CYP3A4 with inhibition constant
(Ki) values (8.5-17 μM) in the range observed efavirenz
plasma concentrations [37,38]. In vitro and in vivo studies
also demonstrated that efavirenz induces CYP3A4 activity
in a concentration- and time-dependent manner
[25,39,40]. Clinical drug-drug interaction studies showed
that efavirenz decreased the systemic exposure of several
CYP3A4 substrates, such as amprenavir, indinavir and
methadone [41-43] in addition to the CYP2C9 and
CYP2C19 substrates [44]. Gliclazide is known to be
metabolized by hepatic microsomal enzymes CYP2C9
primarily and partly by CYP3A4 [33,45]. So the decreased
activity of gliclazide in the presence of efavirenz may be
due to its increased metabolism by hepatic microsomal
enzymes. During initial preclinical studies, chronic
administration of efavirenz was shown to induce its own
metabolism and to increase activities of CYP3A4 in rats,
rhesus monkeys, and humans [39,46,47]. So this autoin-
duction may be the reason behind the less impact of the
efavirenz on the activity of gliclazide following multiple
dose administration in rats and rabbits. Overall the inter-
action between gliclazide and efavirenz appears to be due
to pharmacokinetic rather than pharmacodynamic in
nature. The present study is limited to describe the exact
mechanism of action(s) behind this interaction and it has
to be confirmed by conducting pharmacokinetic interac-
tion studies in different species.
Table 3: Mean percent blood glucose reduction in normal rabbits (N = 6)
Time
(h)
Gliclazide Efavirenz Efavirenz + Gliclazide 
(Single dose treatment)
Efavirenz + Gliclazide 
(Multiple dose treatment)
1 18.30 ± 1.88 -04.36 ± 1.49 09.25 ± 1.37*** 11.54 ± 1.24***
2 24.50 ± 1.24 -06.16 ± 1.93 14.96 ± 1.12*** 16.61 ± 1.21***
3 34.25 ± 0.99 -03.63 ± 1.24 24.97 ± 0.87*** 27.14 ± 0.67***
4 25.92 ± 1.30 -01.48 ± 1.22 14.61 ± 1.22*** 16.97 ± 1.40***
6 24.50 ± 0.96 -00.04 ± 0.98 12.44 ± 1.59*** 14.05 ± 1.53***
8 18.96 ± 2.85 02.09 ± 1.94 10.69 ± 0.70*** 12.28 ± 0.80**
12 10.39 ± 1.32 04.22 ± 2.31 08.89 ± 1.23 10.78 ± 1.86
16 05.71 ± 1.13 06.03 ± 1.87 04.59 ± 1.35 06.51 ± 0.54
20 04.24 ± 1.54 05.31 ± 2.28 03.17 ± 1.29 03.87 ± 2.26
24 02.08 ± 1.47 04.60 ± 1.78 01.42 ± 0.45 02.85 ± 0.90
***Significant at P < 0.001 compared to gliclazide control
**Significant at P < 0.01 compared to gliclazide control
Table 4: Mean percent blood glucose reduction in normal rats (N = 6)
Time
(h)
Gliclazide Nevirapine Nevirapine + Gliclazide*
(Single dose treatment)
Nevirapine + Gliclazide*
(Multiple dose treatment)
1 30.88 ± 1.12 -01.44 ± 0.46 30.43 ± 1.09 30.83 ± 0.94
2 40.72 ± 0.56 02.88 ± 0.45 38.35 ± 0.72 40.49 ± 0.84
3 28.34 ± 0.82 03.96 ± 0.64 26.84 ± 0.79 28.30 ± 0.68
4 23.97 ± 0.79 04.68 ± 0.65 22.90 ± 0.99 23.63 ± 1.13
6 30.90 ± 0.46 02.51 ± 0.66 30.42 ± 1.00 31.53 ± 0.67
8 37.46 ± 1.18 01.43 ± 0.71 35.14 ± 1.23 37.62 ± 1.44
10 24.73 ± 0.69 01.05 ± 1.66 23.61 ± 1.01 25.81 ± 0.76
12 10.52 ± 1.14 00.34 ± 1.40 10.33 ± 1.30 11.80 ± 1.16
*Statistically no significance compared to gliclazide controlDiabetology & Metabolic Syndrome 2009, 1:15 http://www.dmsjournal.com/content/1/1/15
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On other side, nevirapine is known to be an inducer of
CYP3A4 and CYP2B6 [48,49]. There is a minor and non-
significant reduction in gliclazide activity following nevi-
rapine administration in rats and rabbits. The minor and
non-significant decreased activity of gliclazide in the pres-
ence of nevirapine may be due to its increased metabo-
lism by hepatic microsomal enzyme CYP3A4. Even
though the reduction in gliclazide activity in the presence
of nevirapine is minor and non-significant, comparatively
the reduction is more with single dose treatment of nevi-
rapine than multiple dose treatment. Just like efavirenz,
nevirapine is also known to be undergoing autoinduction
of CYP3A4 and CYP2B6 mediated metabolism following
multiple dose administration [50]. So the effect associated
with the multiple dose treatment of nevirapine may be
due to autoinduction of nevirapine. However, either the
single dose or multiple dose treatment of nevirapine has
no significant impact on the gliclazide activity in rats (nor-
mal and diabetic) and rabbits and it confirms the combi-
nation was safe with respect to blood glucose level.
Conclusion
Since the interaction between efavirenz and gliclazide was
seen in two dissimilar species, it is likely to occur in
humans also leading to decreased activity of gliclazide,
which may need dosage adjustment. Hence care should be
taken when the combination is prescribed for their clini-
cal benefit in diabetic patients. Since there is no interac-
tion between nevirapine and gliclazide in any species, it is
likely to be safe combination in humans also. However
the present study warrants further studies to find out the
relevance of these interactions in human beings and to
know the exact mechanism of action behind this interac-
tion(s) if any.
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Table 5: Mean percent blood glucose reduction in diabetic rats (N = 6)
Time
(h)
Gliclazide Nevirapine Nevirapine + Gliclazide*
(Single dose treatment)
Nevirapine + Gliclazide*
(Multiple dose treatment)
1 33.45 ± 1.76 02.08 ± 0.38 32.42 ± 1.47 33.23 ± 1.63
2 42.50 ± 1.40 04.34 ± 1.40 41.68 ± 1.27 42.28 ± 1.32
3 31.87 ± 1.68 04.42 ± 1.62 30.69 ± 1.61 31.66 ± 1.66
4 25.88 ± 1.42 06.11 ± 1.61 25.43 ± 1.47 25.82 ± 1.34
6 36.89 ± 1.30 06.28 ± 1.53 36.25 ± 1.48 36.78 ± 1.38
8 44.46 ± 1.46 03.08 ± 0.54 43.25 ± 1.35 44.37 ± 1.33
10 28.72 ± 1.76 01.67 ± 0.67 27.93 ± 1.55 28.92 ± 1.68
12 24.39 ± 1.81 01.64 ± 0.71 23.81 ± 1.80 24.98 ± 1.83
*Statistically no significance compared to gliclazide control
Table 6: Mean percent blood glucose reduction in normal rabbits (N = 6)
Time
(h)
Gliclazide Nevirapine Nevirapine + Gliclazide*
(Single dose treatment)
Nevirapine + Gliclazide*
(Multiple dose treatment)
1 19.44 ± 2.25 02.08 ± 2.38 21.09 ± 2.93 20.39 ± 2.00
2 26.73 ± 2.57 03.57 ± 2.48 25.38 ± 2.40 26.56 ± 0.90
3 36.18 ± 1.08 05.72 ± 2.23 34.38 ± 0.69 35.18 ± 1.39
4 28.90 ± 3.23 04.59 ± 2.66 26.48 ± 1.47 27.61 ± 1.83
6 24.62 ± 2.00 02.53 ± 1.89 23.21 ± 2.51 25.49 ± 1.05
8 19.13 ± 2.46 02.50 ± 1.42 18.59 ± 1.80 19.63 ± 2.79
12 14.46 ± 1.76 02.82 ± 2.51 12.87 ± 0.86 12.49 ± 1.91
16 08.23 ± 1.85 01.00 ± 2.29 06.36 ± 2.31 07.14 ± 0.99
20 04.99 ± 1.49 01.04 ± 1.54 03.92 ± 1.52 05.33 ± 1.18
24 02.14 ± 1.09 00.63 ± 1.94 01.37 ± 1.43 03.87 ± 1.91
*Statistically no significance compared to gliclazide controlDiabetology & Metabolic Syndrome 2009, 1:15 http://www.dmsjournal.com/content/1/1/15
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